Human ES-derived cardiomyocytes regenerate non-human primate hearts

ceazon

5 W$ c; d6 Z) A2 I3 e& T5 E4 Q' d
. Z0 U2 E* r* S' g  [' `4 _* J; U* b; ?1 h2 c7 Q7 R3 y

8 h" t+ H" n; C! `/ dHuman embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
/ V$ s0 e4 x3 W/ l
% a9 n2 R$ E) X) L0 r, n # O" J6 p+ E7 f4 f8 \! p
- E5 q: w2 W4 Z9 e( x7 W- n
Pluripotent stem cells provide a potential solution to current epidemic rates of heart failure1 by providing human cardiomyocytes to support heart regeneration2. Studies of human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment. However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that that cryopreservation and intra-myocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models7, non-fatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.

bubble_w

求原文

cortex

原文